ロード中...
Cellular and Humoral Immune Responses in Type 1 Diabetic Patients Participating in a Phase III GAD-alum Intervention Trial
OBJECTIVE: GAD formulated in aluminum hydroxide (GAD-alum) has previously been shown to induce preservation of residual insulin secretion in recent-onset type 1 diabetes, but recent phase II and III GAD-alum trials failed to reach primary outcomes. The European phase III study was therefore closed a...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Diabetes Association
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3816912/ https://ncbi.nlm.nih.gov/pubmed/23863909 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc12-2251 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|